PRESS RELEASE DUBLIN.

The acquisition of Auden Mckenzie is certainly a strategic combination that makesActavisthe number 1 generic organization in theUKand aligns with this strategy to establish a leading position in all of our marketplaces, franchises and therapeutic categories, saidBrent Saunders, CEO and President of Actavis. Auden Mckenzie's expertise in the advancement and commercialization of high value, technically demanding formulations as well as specialized and niche opportunities is complementary to and expandsActavis'UKbusiness concentrate, saidRobert Stewart, Executive Vice President Actavis, and President, Generics and Global Operations. The opportunity to combine this profitable and growing company in to the Actavis UK business demonstrates our commitment to invest in and expand strategically inside our global generics business.For these restricted analyses, we included patients who were admitted during the period from 5:00 p.m. Through 4:59 a.m., because these patients were evaluated by intensivists on intervention nights routinely. Second, the availability of beds on the wards could affect the length of stay in the ICU; consequently, for patients who had been discharged to a general ward, we recalculated the length of stay in the ICU as enough time from ICU entrance before patients were deemed prepared for ICU discharge, as determined by an electronic obtain a bed in the overall ward. Third, we recoded the discharge disposition of most patients who had been discharged to home-centered hospice care as deaths, a practice consistent with that in previous studies.14 Fourth, we redefined the publicity variable as a time-various covariate representing the cumulative proportion of nights subjected to the intervention.24,25 On every day of a patient’s stay in the ICU, the cumulative publicity was calculated as the amount of intervention nights divided by the full total number of nights up compared to that day.